false
0001054102
0001054102
2026-10-14
2026-10-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 14, 2026
INTERPACE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
0-24249 |
|
22-2919486 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
Waterview
Plaza, Suite 310, 2001 Route 46
Parsippany,
NJ 07054
(Address, including zip code, of principal executive offices)
(855)
776-6419
Registrant’s
telephone number, including area code
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
October 14, 2026, Interpace Biosciences, Inc. (the “Company”) issued a press release announcing preliminary results for the third quarter
ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
Number |
|
Description |
| 99.1 |
|
Press Release dated October 14, 2026 |
| 104 |
|
Cover Page Interactive
Data File (formatted as Inline XBRL) |
Forward-Looking
Statements
This
report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this report that are not historical facts may be considered “forward-looking statements,” including, but not limited to,
statements regarding the Company’s preliminary results for the quarter ended September 30, 2026. These statements are based on
management’s current expectations and information available as of the date of this report and are subject to risks, uncertainties,
closing adjustments and other factors that could cause actual results to differ materially. Forward-looking statements are typically,
but not always, identified by the use of words such as “may,” “would,” “believe,” “intend,”
“plan,” “anticipate,” “estimate,” “expect,” and other similar terminology. Forward-looking
statements are based on current expectations of management and upon what management believes to be reasonable assumptions based on information
currently available to it, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ
materially from the expectations set forth in the forward-looking statements. Such risks and uncertainties include, but are not limited
to, risks related to preliminary financial results, including the risks that the preliminary financial results reported in Exhibit
99.1 reflect information available to the Company only at this time and may differ from actual results, including in connection with
the Company’s completion of financial closing procedures, risks and uncertainties associated with the Company’s business
and finances in general, as well as other risks detailed in the Company’s recent filings on Forms 10-K and 10-Q with the
SEC. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances,
or to reflect the occurrence of unanticipated events.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
October 15, 2026 |
INTERPACE
BIOSCIENCES, INC. |
| |
|
|
| |
By: |
/s/
Thomas W. Burnell |
| |
Name: |
Thomas
W. Burnell |
| |
Title: |
President
and Chief Executive Officer |
Exhibit
99.1
Interpace
Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
| ● | Preliminary
Q3 2026 revenue expected to range from $10.1 million to $10.4 million |
| ● | Expected
quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 |
| ● | Expected
year-over-year growth of approximately 15% to 18% compared with Q3 2025 |
PARSIPPANY,
NJ, October 14, 2026 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID:
IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1
million to $10.4 million.
The
expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter
of 2026 and an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025.
The
estimated revenue presented in this release is preliminary and unaudited, is based on information currently available to management,
and remains subject to completion of the Company’s quarter-end closing procedures and review by the Company’s independent
registered public accounting firm. Actual results may differ, including materially, from the range presented above. The Company expects
to report complete financial results for the third quarter of 2026 at a later date.
About
Interpace Biosciences
Interpace
Biosciences is an emerging leader in enabling personalized medicine through specialized molecular diagnostic tests and related services.
The Company’s commercialized thyroid tests include ThyGeNEXT® and ThyraMIR®v2, which are used together to support the evaluation
of indeterminate thyroid nodules. For more information, please visit www.interpace.com.
Free
Writing Prospectus
The
issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering
to which this free writing prospectus communication relates. Before you invest, you should read the prospectus in that registration statement
and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these
documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer
participating in the offering will arrange to send you the prospectus if you request it by calling 612-326-1305. You may also access
the registration statement (including the prospectus) through the following link:
https://www.sec.gov/Archives/edgar/data/1054102/000149315226045187/forms-1a.htm
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding
the Company’s expected revenue for the third quarter of 2026 and the timing of its complete financial results. These statements
are based on management’s current expectations and information available as of the date of this release and are subject to risks,
uncertainties, closing adjustments and other factors that could cause actual results to differ materially. Such factors include those
described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. The preliminary,
unaudited financial information in this release has not been reviewed by the Company’s independent registered public accounting
firm and is subject to change as the Company completes its quarter-end closing and review procedures. The Company’s expected revenues
for the third quarter of 2026 may not be indicative of the Company’s net income for such period or for full year results. Readers
should not place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking
statement, except as required by law.
Contacts
Investor
Relations
Interpace
Biosciences, Inc.
(855)
776-6419
Info@Interpace.com
